Enter multiple symbols separated by commas

Medical Therapy Stocks Prescribed by Analyst

More than 4.1 million Americans live with hepatitis C, a viral infection of the liver. That's one of several reasons why Jason Kolbert, a biotechnology analyst at Susquehanna Financial Group, advised "Squawk Box" viewers to stock up on therapy stocks.

The analyst pointed to Vertex Pharmaceuticals , for example, which leads the market with its VX-950 -- “probably the most potent drug in the field” for the disease, he said.

And expect consumers to use a combination of therapies, Kolbert said. Some 50% of people living with the disease are in need of ongoing help: “Half the people who have hepatitis C and take these therapies are cured,” he said. “But, the other half aren’t. And there are very few treatments available to them.”

Contact Squawk Box


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.
  • Showtimes

    Weekdays 6a ET
    Weekdays 13:00 CET
    Weekdays 18:00 SIN/HK
    Weekdays 20:00 SYD